Vertex Pharmaceuticals Rating Lowered to Outperform at RBC Capital (VRTX)
VRTX has been the subject of a number of other recent research reports. Analysts at Leerink Swann reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note to investors on Tuesday. Separately, analysts at Summer Street reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note to investors on Tuesday. Finally, analysts at Barclays Capital (NYSE: BCS) raised their price target on shares of Vertex Pharmaceuticals from $44.00 to $77.00 in a research note to investors on Tuesday. They now have an “overweight” rating on the stock.
Vertex Pharmaceuticals traded up 1.79% on Thursday, hitting $61.27. Vertex Pharmaceuticals has a 52-week low of $26.50 and a 52-week high of $64.50. The company has a market cap of $12.920 billion and a price-to-earnings ratio of 42.81.
Vertex Pharmaceuticals last posted its quarterly earnings results on Thursday, April 26th. The company reported $0.43 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.57 by $0.14. The company’s quarterly revenue was up 496.5% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $0.70 EPS next quarter.
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.